| scholarly article | Q13442814 |
| P50 | author | Dingxie Liu | Q55459885 |
| P2093 | author name string | Avaniyapuram Kannan Murugan | |
| Mingzhao Xing | |||
| Ermal Bojdani | |||
| Chongfei Yang | |||
| P2860 | cites work | Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer | Q37767709 |
| The long and winding road to rational treatment of cancer associated with LKB1/AMPK/TSC/mTORC1 signaling | Q37831801 | ||
| The GTPase-activating NF1 fragment of 91 amino acids reverses v-Ha-Ras-induced malignant phenotype | Q38315079 | ||
| Decreased expression of the RAS-GTPase activating protein RASAL1 is associated with colorectal tumor progression. | Q39920036 | ||
| The tumor suppressor neurofibromin confers sensitivity to apoptosis by Ras-dependent and Ras-independent pathways | Q40210019 | ||
| Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis. | Q40583206 | ||
| Identification of a dominant negative mutant of Sprouty that potentiates fibroblast growth factor- but not epidermal growth factor-induced ERK activation | Q40787356 | ||
| The neurofibromatosis type 1 gene and its protein product, neurofibromin. | Q40890889 | ||
| Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. | Q53569559 | ||
| Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors. | Q54513531 | ||
| Large majority of single-nucleotide mutations along the dystrophin gene can be explained by more than one mechanism of mutagenesis | Q73441578 | ||
| Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer | Q79819385 | ||
| Tumour suppressors: Role of nuclear PTEN revealed | Q83751989 | ||
| Global cancer statistics | Q22241238 | ||
| Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer | Q24685746 | ||
| Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? | Q27690752 | ||
| Crystal structure of the GTPase-activating domain of human p120GAP and implications for the interaction with Ras | Q27734180 | ||
| cDNA cloning and characterization of ret activated in a human papillary thyroid carcinoma cell line | Q28117244 | ||
| Dual-specificity phosphatase 5 (DUSP5) as a direct transcriptional target of tumor suppressor p53 | Q28204132 | ||
| Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer | Q28253304 | ||
| A genetic screen identifies PITX1 as a suppressor of RAS activity and tumorigenicity | Q28257022 | ||
| Stops along the RAS pathway in human genetic disease | Q28300658 | ||
| A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns] | Q31942209 | ||
| Ras proteins: recent advances and new functions. | Q33771484 | ||
| The NF1 tumor suppressor critically regulates TSC2 and mTOR. | Q33841600 | ||
| B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression | Q33934897 | ||
| Spred is a Sprouty-related suppressor of Ras signalling | Q34086194 | ||
| Molecular pathogenesis and mechanisms of thyroid cancer | Q34329018 | ||
| Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype | Q34664172 | ||
| Genetics of neurofibromatosis 1 and the NF1 gene | Q34982028 | ||
| Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation | Q35578577 | ||
| Epigenetic silencing of a Ca(2+)-regulated Ras GTPase-activating protein RASAL defines a new mechanism of Ras activation in human cancers. | Q35927921 | ||
| BRAF mutation in thyroid cancer | Q36157661 | ||
| The genetic and molecular pathogenesis of NF1 and NF2. | Q36526233 | ||
| BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications | Q36972859 | ||
| Raf kinase inhibitory protein: a signal transduction modulator and metastasis suppressor | Q37124492 | ||
| LKB1; linking cell structure and tumor suppression | Q37333592 | ||
| Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin | Q37373348 | ||
| The RASSF proteins in cancer; from epigenetic silencing to functional characterization | Q37432498 | ||
| P433 | issue | 21 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | thyroid cancer | Q826522 |
| P304 | page(s) | 1617-1627 | |
| P577 | publication date | 2013-10-17 | |
| P1433 | published in | Journal of the National Cancer Institute | Q400279 |
| P1476 | title | Identification of RASAL1 as a major tumor suppressor gene in thyroid cancer | |
| P478 | volume | 105 |
| Q49544932 | Altered Epigenetic Mechanisms in Thyroid Cancer Subtypes |
| Q64240262 | CRISPR-induced RASGAP deficiencies in colorectal cancer organoids reveal that only loss of NF1 promotes resistance to EGFR inhibition |
| Q30356267 | Cattle genome-wide analysis reveals genetic signatures in trypanotolerant N'Dama. |
| Q99727599 | Characterization of BRCA1-deficient premalignant tissues and cancers identifies Plekha5 as a tumor metastasis suppressor |
| Q35234108 | Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing |
| Q36905783 | Characterization of the novel tumor-suppressor gene CCDC67 in papillary thyroid carcinoma |
| Q38687220 | Clinicopathological significance of TERT promoter mutation in papillary thyroid carcinomas: a systematic review and meta-analysis |
| Q93081074 | Current Knowledge of Germline Genetic Risk Factors for the Development of Non-Medullary Thyroid Cancer |
| Q36378640 | Discovery of Stromal Regulatory Networks that Suppress Ras-Sensitized Epithelial Cell Proliferation |
| Q38871173 | EBP1 suppresses growth, migration, and invasion of thyroid cancer cells through upregulating RASAL expression |
| Q37702380 | Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness. |
| Q33358936 | Estrogens and stem cells in thyroid cancer |
| Q33570103 | Germline alterations in RASAL1 in Cowden syndrome patients presenting with follicular thyroid cancer and in individuals with apparently sporadic epithelial thyroid cancer |
| Q90398486 | Global RNA Expression and DNA Methylation Patterns in Primary Anaplastic Thyroid Cancer |
| Q58695373 | High-fidelity CRISPR/Cas9- based gene-specific hydroxymethylation rescues gene expression and attenuates renal fibrosis |
| Q91829086 | JAZF1 Suppresses Papillary Thyroid Carcinoma Cell Proliferation and Facilitates Apoptosis via Regulating TAK1/NF-κB Pathways |
| Q35959029 | MicroRNA-145 inhibits human papillary cancer TPC1 cell proliferation by targeting DUSP6 |
| Q53190179 | Molecular perspectives in differentiated thyroid cancer. |
| Q42014310 | NGS based identification of mutational hotspots for targeted therapy in anaplastic thyroid carcinoma |
| Q27027491 | Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations |
| Q55032450 | Preserved SCN4B expression is an independent indicator of favorable recurrence-free survival in classical papillary thyroid cancer. |
| Q58804586 | Prognosis of FTC compared to PTC and FVPTC: findings based on SEER database using propensity score matching analysis |
| Q51239343 | Prognostic implications of RASAL1 expression in oesophagogastric adenocarcinoma. |
| Q37371518 | Protein tyrosine phosphatase 1B targets PITX1/p120RasGAP thus showing therapeutic potential in colorectal carcinoma. |
| Q41616091 | RAS protein activator-like 1 is functionally involved in hypoxia resistance in breast cancer cells by targeting hypoxia inducible factor-1α. |
| Q34284826 | RASAL1 in thyroid cancer: promise from a new friend |
| Q92055317 | RASAL1 induces to downregulate the SCD1, leading to suppression of cell proliferation in colon cancer via LXRα/SREBP1c pathway |
| Q49414860 | RASAL1 inhibits HepG2 cell growth via HIF-2α mediated gluconeogenesis |
| Q36629559 | REC8 is a novel tumor suppressor gene epigenetically robustly targeted by the PI3K pathway in thyroid cancer |
| Q37693498 | The Role of STAT3 in Thyroid Cancer |
| Q35906347 | The diagnostic application of RNA sequencing in patients with thyroid cancer: an analysis of 851 variants and 133 fusions in 524 genes |
| Q37580248 | β-catenin signaling is required for RAS-driven thyroid cancer through PI3K activation. |
Search more.